Search clinical trials for: B-cell Malignancy

Total 3616 results

Children's Hospital Medical Center, Cincinnati

Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Lymphoma | Follicular Lymphoma | Leukemia | B Cell Lymphoma | Hodgkin Lymphoma | Burkitt Lymphoma | AML | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm | T-cell Lymphoma | Peripheral T Cell Lymphoma and other conditions

United States
Joshua Sasine, MD, PhD

Recruiting

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Multiple Myeloma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Large B-cell Lymphoma

United States
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Large B-cell Lymphoma | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

United States
Carna Biosciences, Inc.

Recruiting

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | B-cell Malignancy

United States
Beijing Boren Hospital

Recruiting

Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia

China
BeiGene

Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Burton Tyrosine Kinase-Targeted Protein-Degrader

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Richter's Transformation | DLBCL Unclassifiable

China
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Primary Central Nervous System Lymphoma (PCNSL) | Marginal Zone Lymphoma (MZL) | Waldenstrom Macroglobulinemia (WM) | Diffuse Large B Cell Lymphoma (DLBCL)

United States, United Kingdom, Netherlands
Fundamenta Therapeutics, Ltd.
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

B-cell Malignancy

China
Fundamenta Therapeutics, Ltd.
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

B-cell Malignancy

China
AIDS Malignancy Consortium
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center

Not yet recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

HIV Infection | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent... and other conditions
BeiGene

Recruiting

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | B-cell Malignancy

United States, Spain, Italy, Australia, France, Korea, Republic of, Canada, Georgia, Sweden, Germany, Moldova, Republic of
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Recruiting

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | MALT Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Indolent Lymphoma | Refractory B-Cell Lymphoma

United States, Australia, China
Nanfang Hospital of Southern Medical University

Recruiting

Induced-T Cell Like NK Cells for B Cell Malignancies

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | B Cell Leukemia | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
Fundamenta Therapeutics, Ltd.
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

Recruiting

Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies

B Cell Malignancy

China
Memorial Sloan Kettering Cancer Center
Actinium Pharmaceuticals

Recruiting

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma | B-ALL | DLBCL | DLBCL, Nos Genetic Subtypes | B ALL | Dlbcl-Ci | DLBCL Unclassifiable | DLBCL Activated B-Cell Type | DLBCL Germinal Center B-Cell Type | HGBL | HGBL, Nos

United States
Fundamenta Therapeutics, Ltd.
Anhui Provincial Hospital

Recruiting

Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

B Cell Malignancy

China
AIDS Malignancy Consortium
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center; Janssen... and other collaborators

Recruiting

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Plasmablastic Lymphoma | Ann Arbor Stage I Diffuse Large B-Cell Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma

United States
University Hospital, Clermont-Ferrand
Fondation Apicil; Association des foulées de la Haute Lozère; Association CEMSBM and other collaborators

Recruiting

Early Palliative Care for Patients With Haematological Malignancies (CALVI)

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Diffuse Large B Cell Lymphoma | Palliative Care

France
Dana-Farber Cancer Institute
The Leukemia and Lymphoma Society

Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Myelodysplastic-Myeloproliferative Diseases | Waldenstrom Macroglobulinemia | Smoldering Multiple Myeloma | Chronic Lymphocytic Leukemia (CLL) | Hematological Malignancies | Monoclonal Gammopathy of Undetermined Significance (MGUS) | B-cell Malignancy, Low-grade | Myelodysplastic Syndrome With Low-grade... and other conditions

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

B-cell Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Adult B Cell ALL

United States, Spain, Canada, France, Germany, Australia
Michael A. Thompson, MD, PhD
Vince Lombardi Cancer Clinic

Withdrawn

B-Cell Hematologic Malignancy Vaccination Registry (HMvax-Regist)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Waldenstrom Macroglobulinemia | Monoclonal Gammopathy of Undetermined Significance | Hematological Malignancies | B-Cell Chronic Lymphocytic Leukemia | Lymphocytosis

United States
Calibr, a division of Scripps Research

Enrolling by invitation

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Transformed Follicular Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Primary Mediastinal Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Mantle Cell Lymphoma (MCL) | Follicular... and other conditions

United States
Calibr, a division of Scripps Research

Active, not recruiting

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Transformed Follicular Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Primary Mediastinal Large B Cell Lymphoma | Follicular Lymphoma (FL) | Marginal Zone Lymphoma... and other conditions

United States
AIDS Malignancy Consortium
Center for International Blood and Marrow Transplant Research

Active, not recruiting

Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell (CS22-03)

HIV Infections | Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Follicular Lymphoma | Leukemia | Leukemia, Lymphoblastic | HIV Associated Lymphoma | HIV Disease; Lymphoma

United States
Nurix Therapeutics, Inc.

Active, not recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Primary Central Nervous System Lymphoma (PCNSL) | Marginal Zone Lymphoma (MZL) | Waldenstrom Macroglobulinemia (WM)

United States
Baptist Health South Florida

Withdrawn

Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies

Non-Hodgkin Lymphoma | Hematologic Malignancy | B-Cell Lymphoid Malignancies

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Minimal Residual Disease | Therapy-Related Acute Myeloid Leukemia | Therapy-Related Myelodysplastic... and other conditions

United States
Eisai Limited

Completed

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Ovarian Cancer | Triple Negative Breast Cancer | Malignant Solid Tumour | Advanced Melanoma | B-cell Malignancy, Low-grade

United Kingdom
Caribou Biosciences, Inc.

Enrolling by invitation

CB-Long-Term Safety Study (CB-LTSS) (CB-LTSS)

Lymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Hematologic Malignancy | Relapsed Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin's Lymphoma

United States
Epizyme, Inc.

Completed

Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer

Solid Tumor | Mesothelioma | Rhabdoid Tumor | Hematologic Malignancy | Advanced Malignancies | Synovial Sarcoma | Renal Medullary Carcinoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Non-Hodgkin Lymphoma (NHL) | All Malignancies | Epithelioid Sarcoma (ES)

Spain, United States
Bristol-Myers Squibb
Nektar Therapeutics

Terminated

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020)

Ewing Sarcoma | Ependymoma | Medulloblastoma | Neuroblastoma | Rhabdomyosarcoma | High-grade Glioma | Leukemia and Lymphoma | Miscellaneous Brain Tumors | Miscellaneous Solid Tumors | Relapsed, Refractory Malignant Neoplasms

United States, Australia, France, Germany, Italy, Spain
Molecular Templates, Inc.

Terminated

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001)

Leukemia, Lymphocytic, Chronic, B-Cell | Diffuse Large B Cell Lymphoma | Blood Cancer | Hematological Malignancy | Small Lymphocytic Leukemia | Non-Hodgkin's B-cell Lymphoma

United States, Canada, Georgia, Belarus, Spain, Israel, Moldova, Republic of, Poland, Serbia, Ukraine
Novartis Pharmaceuticals

Completed

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Soft Tissue Sarcoma | Small Cell Lung Cancer | Gastric Adenocarcinoma | Diffuse Large B Cell Lymphoma | Esophageal Adenocarcinoma | Ovarian Adenocarcinoma | Castration Resistant Prostate Adenocarcinoma | Advanced Well-differentiated Neuroendocrine Tumors

United States
National Cancer Institute (NCI)

Terminated

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Leukemia | Chronic | Lymphocytic | B-Cell

United States
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.; Avalon GloboCare Corp.

Completed

CD19-CAR-T in B-cell Malignancies Patients

B-cell Malignancy

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients

B Cell Malignancy

China
Uppsala University
Uppsala University Hospital; AFA Insurance

Completed

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

B-Cell Lymphoma | B-cell Leukemia

Sweden
Novartis Pharmaceuticals

Terminated

Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (SIGNATURE)

Tumors With Aberrations in ALK or ROS1

United States
Shanghai Tong Ren Hospital
Gracell Biotechnology Ltd.

Unknown

CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

B-cell Lymphoma | B-cell Malignancy | B-Cell Acute Lymphoblastic Leukaemia

China
Sunesis Pharmaceuticals

Terminated

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Lymphoplasmacytoid Lymphoma

United States
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma

Lymphoma | Nonneoplastic Condition

United States
Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Hematological Malignancy With Novel CAR-T Cells.

Multiple Myeloma | B-cell Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
National Cancer Institute (NCI)

Completed

Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Jazz Pharmaceuticals

Withdrawn

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Hematologic Malignancy
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
MedImmune LLC

Completed

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma

United States, France, Spain, Canada, Turkey, Israel, Germany, Russian Federation, Czechia, Hungary, Poland
Celldex Therapeutics

Completed

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma | Marginal Zone B Cell Lymphoma) | Any T-cell Malignancy | Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma | Hormone-refractory Prostate Adenocarcinoma, Ovarian... and other conditions

United States
Ohio State University Comprehensive Cancer Center

Completed

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Indolent or Intermediate Grade B-cell Malignancy

United States

Search clinical trials for: B-cell Malignancy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations